Mitochondrial ROS accumulation inhibiting JAK2/STAT3 pathway is a critical modulator of CYT997-induced autophagy and apoptosis in gastric cancer

Mitochondrial quality control in pulmonary fibrosis

(2020) Jennifer L. Larson-Casey et al.   Redox Biology

The multifaceted role of reactive oxygen species in tumorigenesis

(2020) Anuradha Kirtonia et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

Salmonella Enteritidis Effector AvrA Suppresses Autophagy by Reducing Beclin-1 Protein

(2020) Yang Jiao et al.   Frontiers in Immunology

The role of mitochondrial-related nuclear genes in age-related common disease

(2020) Huanzheng Li et al.   MITOCHONDRION

CYT997(Lexibulin) induces apoptosis and autophagy through the activation of mutually reinforced ER stress and ROS in osteosarcoma

(2019) Zongyi Wang et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Formononetin-induced oxidative stress abrogates the activation of STAT3/5 signaling axis and suppresses the tumor growth in multiple myeloma preclinical model

(2018) Chulwon Kim et al.   CANCER LETTERS

Hispidulin suppresses cell growth and metastasis by targeting PIM1 through JAK2/STAT3 signaling in colorectal cancer

(2018) Kaili Liu et al.   CANCER SCIENCE

ROS signalling in the biology of cancer

(2018) Jennifer N. Moloney et al.   SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY

Amentoflavone suppresses hepatocellular carcinoma by repressing hexokinase 2 expression through inhibiting JAK2/STAT3 signaling

(2018) Bo Liu et al.   BIOMEDICINE & PHARMACOTHERAPY

Comprehensive review on how platinum- and taxane-based chemotherapy of ovarian cancer affects biology of normal cells

(2018) Justyna Mikuła-Pietrasik et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

The role of cellular reactive oxygen species in cancer chemotherapy

(2018) Haotian Yang et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Cisplatin induces autophagy to enhance hepatitis B virus replication via activation of ROS/JNK and inhibition of the Akt/mTOR pathway

(2018) Xuemei Chen et al.   FREE RADICAL BIOLOGY AND MEDICINE

Cell death response to anti-mitotic drug treatment in cell culture, mouse tumor model and the clinic

(2017) Jue Shi et al.   ENDOCRINE-RELATED CANCER

Augmentation of the anticancer activity of CYT997 in human prostate cancer by inhibiting Src activity

(2017) Yong Teng et al.   Journal of Hematology & Oncology

Differences in the multimodal treatment of gastric cancer: East versus west

(2017) Ashley Russo et al.   JOURNAL OF SURGICAL ONCOLOGY

Paclitaxel induces apoptosis of esophageal squamous cell carcinoma cells by downregulating STAT3 phosphorylation at Ser727

(2017) Xiaolong Zhang et al.   ONCOLOGY REPORTS

ROS Are Good

(2017) Ron Mittler   TRENDS IN PLANT SCIENCE

Selinexor (KPT-330) has antitumor activity against anaplastic thyroid carcinoma in vitro and in vivo and enhances sensitivity to doxorubicin

(2017) Manoj Garg et al.   Scientific Reports

Signal transducer and activator of transcription 3 as a therapeutic target for cancer and the tumor microenvironment

(2016) Byung-Hak Kim et al.   ARCHIVES OF PHARMACAL RESEARCH

Early investigational tubulin inhibitors as novel cancer therapeutics

(2016) Kunal Nepali et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Momordin Ic couples apoptosis with autophagy in human hepatoblastoma cancer cells by reactive oxygen species (ROS)-mediated PI3K/Akt and MAPK signaling pathways

(2016) Yashi Mi et al.   FREE RADICAL BIOLOGY AND MEDICINE

Synergistic antitumor activity of rapamycin and EF24 via increasing ROS for the treatment of gastric cancer

(2016) Weiqian Chen et al.   Redox Biology

Carnosic acid inhibits STAT3 signaling and induces apoptosis through generation of ROS in human colon cancer HCT116 cells

(2015) Do-Hee Kim et al.   MOLECULAR CARCINOGENESIS

Targeting Microtubules by Natural Agents for Cancer Therapy

(2014) E. Mukhtar et al.   MOLECULAR CANCER THERAPEUTICS

Mitochondrial Reactive Oxygen Species (ROS) and ROS-Induced ROS Release

(2014) Dmitry B. Zorov et al.   PHYSIOLOGICAL REVIEWS

The microtubule depolymerizing agent CYT997 effectively kills acute myeloid leukemia cells via activation of caspases and inhibition of PI3K/Akt/mTOR pathway proteins

(2013) XIAOHUI CHEN et al.   Experimental and Therapeutic Medicine

Cancer statistics for Hispanics/Latinos, 2012

(2012) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Phase I, pharmacokinetic and pharmacodynamic evaluation of CYT997, an orally-bioavailable cytotoxic and vascular-disrupting agent

(2012) Matthew Burge et al.   INVESTIGATIONAL NEW DRUGS

An Overview of Tubulin Inhibitors That Interact with the Colchicine Binding Site

(2012) Yan Lu et al.   PHARMACEUTICAL RESEARCH

Dissecting the dynamic turnover of GFP-LC3 in the autolysosome

(2011) Hong-Min Ni et al.   Autophagy

Treatment of resectable gastric cancer

(2011) Johan L. Dikken et al.   Therapeutic Advances in Gastroenterology

Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent

(2010) J D Lickliter et al.   BRITISH JOURNAL OF CANCER

Microtubule-binding agents: a dynamic field of cancer therapeutics

(2010) Charles Dumontet et al.   NATURE REVIEWS DRUG DISCOVERY

Regulation of autophagy by ROS: physiology and pathology

(2010) Ruth Scherz-Shouval et al.   TRENDS IN BIOCHEMICAL SCIENCES

Discovery of CYT997: a structurally novel orally active microtubule targeting agent

(2009) Christopher J. Burns et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

The Double-Edged Sword of Autophagy Modulation in Cancer

(2009) E. White et al.   CLINICAL CANCER RESEARCH

Gastric cancer

(2009) Henk H Hartgrink et al.   LANCET

CYT997: a novel orally active tubulin polymerization inhibitor with potent cytotoxic and vascular disrupting activity in vitro and in vivo

(2009) C. J. Burns et al.   MOLECULAR CANCER THERAPEUTICS

The function of Stat3 in tumor cells and their microenvironment

(2008) Bernd Groner et al.   SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY